BR112022019508A2 - Moduladores de mtorc1 e seus usos - Google Patents
Moduladores de mtorc1 e seus usosInfo
- Publication number
- BR112022019508A2 BR112022019508A2 BR112022019508A BR112022019508A BR112022019508A2 BR 112022019508 A2 BR112022019508 A2 BR 112022019508A2 BR 112022019508 A BR112022019508 A BR 112022019508A BR 112022019508 A BR112022019508 A BR 112022019508A BR 112022019508 A2 BR112022019508 A2 BR 112022019508A2
- Authority
- BR
- Brazil
- Prior art keywords
- mtorc1
- modulators
- diseases
- salts
- treatment
- Prior art date
Links
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 abstract 2
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Burglar Alarm Systems (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
MODULADORES DE mTORC1 E SEUS USOS. A descrição provê compostos e sais que mostram alta seletividade e atividade inibidora para mTORC1 e seus usos para o tratamento de doenças.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001187P | 2020-03-27 | 2020-03-27 | |
| US202063001177P | 2020-03-27 | 2020-03-27 | |
| US202063001144P | 2020-03-27 | 2020-03-27 | |
| US202063019176P | 2020-05-01 | 2020-05-01 | |
| US202063054768P | 2020-07-21 | 2020-07-21 | |
| US202063054763P | 2020-07-21 | 2020-07-21 | |
| US202063054762P | 2020-07-21 | 2020-07-21 | |
| PCT/US2021/024536 WO2021195599A1 (en) | 2020-03-27 | 2021-03-26 | Mtorc1 modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019508A2 true BR112022019508A2 (pt) | 2022-11-16 |
Family
ID=77892684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019508A BR112022019508A2 (pt) | 2020-03-27 | 2021-03-26 | Moduladores de mtorc1 e seus usos |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11634432B2 (pt) |
| EP (1) | EP4126229A4 (pt) |
| JP (1) | JP2023530778A (pt) |
| KR (1) | KR20230084095A (pt) |
| CN (1) | CN115776907A (pt) |
| AU (1) | AU2021241718A1 (pt) |
| BR (1) | BR112022019508A2 (pt) |
| CA (1) | CA3173722A1 (pt) |
| IL (1) | IL296828A (pt) |
| MX (1) | MX2022011964A (pt) |
| WO (1) | WO2021195599A1 (pt) |
| ZA (1) | ZA202210888B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3813946T3 (da) | 2018-06-15 | 2024-08-19 | Janssen Pharmaceutica Nv | Rapamycin-analoger og anvendelser deraf |
| EA202191983A1 (ru) | 2019-01-22 | 2021-12-01 | Аеовиан Фармасьютикалз, Инк. | МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ |
| JP2023506410A (ja) | 2019-12-05 | 2023-02-16 | アナクリア セラピューティクス， インコーポレイテッド | ラパマイシン類似体及びその使用 |
| BR112022019508A2 (pt) | 2020-03-27 | 2022-11-16 | Aeovian Pharmaceuticals Inc | Moduladores de mtorc1 e seus usos |
| CN116322677A (zh) * | 2020-07-21 | 2023-06-23 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| WO2024211738A1 (en) * | 2023-04-07 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Selective rapamycin analogs and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| SG64372A1 (en) | 1993-12-17 | 1999-04-27 | Novartis Ag | Rapamycin derivatives |
| US6187757B1 (en) * | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| AU783158B2 (en) * | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
| WO2006136175A2 (en) | 2005-06-22 | 2006-12-28 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor |
| GB0601406D0 (en) * | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
| WO2009131631A1 (en) | 2008-04-14 | 2009-10-29 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
| EP2675450B1 (en) * | 2011-02-16 | 2016-02-10 | Novartis AG | Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases |
| WO2014153118A1 (en) * | 2013-03-14 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
| WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| CN107073066B (zh) | 2014-09-11 | 2021-09-17 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
| WO2017038925A1 (ja) | 2015-09-03 | 2017-03-09 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| WO2017044720A1 (en) | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CN108926533B (zh) | 2017-05-24 | 2022-03-25 | 江苏天士力帝益药业有限公司 | 一种替西罗莫司脂质体及其制备方法 |
| US10478561B2 (en) | 2017-08-03 | 2019-11-19 | Minhong Yu | Wireless transmission system with integrated sensing capability |
| UY37900A (es) * | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
| DK3813946T3 (da) | 2018-06-15 | 2024-08-19 | Janssen Pharmaceutica Nv | Rapamycin-analoger og anvendelser deraf |
| WO2020076738A2 (en) | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| CN113260619A (zh) | 2018-12-18 | 2021-08-13 | 诺华股份有限公司 | 雷帕霉素衍生物 |
| EA202191983A1 (ru) | 2019-01-22 | 2021-12-01 | Аеовиан Фармасьютикалз, Инк. | МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ |
| JP2023506410A (ja) | 2019-12-05 | 2023-02-16 | アナクリア セラピューティクス， インコーポレイテッド | ラパマイシン類似体及びその使用 |
| BR112022019508A2 (pt) | 2020-03-27 | 2022-11-16 | Aeovian Pharmaceuticals Inc | Moduladores de mtorc1 e seus usos |
| CN116322677A (zh) | 2020-07-21 | 2023-06-23 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| BR112023014287A2 (pt) | 2021-01-22 | 2023-11-21 | Janssen Pharmaceutica Nv | Análogos de rapamicina e usos dos mesmos |
-
2021
- 2021-03-26 BR BR112022019508A patent/BR112022019508A2/pt unknown
- 2021-03-26 CA CA3173722A patent/CA3173722A1/en active Pending
- 2021-03-26 AU AU2021241718A patent/AU2021241718A1/en active Pending
- 2021-03-26 WO PCT/US2021/024536 patent/WO2021195599A1/en active Application Filing
- 2021-03-26 JP JP2023502874A patent/JP2023530778A/ja active Pending
- 2021-03-26 EP EP21775952.1A patent/EP4126229A4/en active Pending
- 2021-03-26 KR KR1020227036354A patent/KR20230084095A/ko not_active Application Discontinuation
- 2021-03-26 MX MX2022011964A patent/MX2022011964A/es unknown
- 2021-03-26 IL IL296828A patent/IL296828A/en unknown
- 2021-03-26 CN CN202180038254.0A patent/CN115776907A/zh active Pending
-
2022
- 2022-03-01 US US17/683,549 patent/US11634432B2/en active Active
- 2022-06-03 US US17/832,240 patent/US11603377B2/en active Active
- 2022-10-03 ZA ZA2022/10888A patent/ZA202210888B/en unknown
-
2023
- 2023-03-08 US US18/180,517 patent/US20240002399A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11603377B2 (en) | 2023-03-14 |
| MX2022011964A (es) | 2022-12-02 |
| JP2023530778A (ja) | 2023-07-19 |
| ZA202210888B (en) | 2024-02-28 |
| US20220235069A1 (en) | 2022-07-28 |
| EP4126229A4 (en) | 2024-04-17 |
| US11634432B2 (en) | 2023-04-25 |
| CA3173722A1 (en) | 2021-09-30 |
| US20240002399A1 (en) | 2024-01-04 |
| WO2021195599A1 (en) | 2021-09-30 |
| US20220332727A1 (en) | 2022-10-20 |
| IL296828A (en) | 2022-11-01 |
| EP4126229A1 (en) | 2023-02-08 |
| KR20230084095A (ko) | 2023-06-12 |
| CN115776907A (zh) | 2023-03-10 |
| AU2021241718A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019508A2 (pt) | Moduladores de mtorc1 e seus usos | |
| BR112023015527A2 (pt) | Inibidores de cdk e métodos de uso destes | |
| CO2021009078A2 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
| BR112018000635A2 (pt) | compostos aza substituídos como inibidores irak-4 | |
| BR112018000624A2 (pt) | compostos de indazol e azaindazol como inibidores de irak-4 | |
| CL2020002573A1 (es) | Inhibidores atf6 y sus usos. | |
| CO2022009438A2 (es) | Fluoroalquil-oxadiazoles y sus usos | |
| CL2018000687A1 (es) | Nuevos compuestos bicíclicos como inhibidores de atx. | |
| BR112017003745A2 (pt) | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico | |
| CO2023010023A2 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| CL2019001481A1 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos. | |
| CL2020003008A1 (es) | Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas | |
| UY37379A (es) | Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades | |
| CL2018003260A1 (es) | Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos. | |
| CL2021001536A1 (es) | 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden | |
| BR112022010754A2 (pt) | Análogos de rapamicina e usos dos mesmos | |
| BR112019024322A2 (pt) | Compostos e composições terapêuticos e métodos de uso dos mesmos | |
| BR112022014949A2 (pt) | Compostos e usos dos mesmos | |
| CO2018001237A2 (es) | Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos | |
| BR112021019854A2 (pt) | Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares | |
| BR112019007543A2 (pt) | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase | |
| BR112021019703A2 (pt) | Compostos heterocíclicos e usos dos mesmos | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| BR112017003231A2 (pt) | compostos heterobicíclicos e seu uso para o tratamento da tuberculose | |
| CL2021000930A1 (es) | Piridazinas novedosas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024006050-7 PROTOCOLO 870240026465 EM 26/03/2024 20:54. |